ArticleNature2020
Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 137 papers.
0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed
17.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 194 citations in OpenAlex.
- Brief Report: Low-Dose Methotrexate Does Not Affect Measures of HIV-1 Persistence in Individuals With Chronically Treated HIV-1 Infection.Journal of acquired immune deficiency syndromes (1999) · 2024Trial
- Trial
- Longitudinal study reveals HIV-1-infected CD4+ T cell dynamics during long-term antiretroviral therapy.The Journal of clinical investigation · 2020Trial
- Enhancing HIV-1-specific CAR-T cell functional activity by treatment with a novel cytokine-based scaffold with IL-15 superagonist and TGF-β-neutralizing activity.Journal of virology · 2026Article
- HIV cure: from early therapies to cutting-edge strategies.Journal of neurovirology · 2026Review
- The Rectal Mucosal Myeloid Niche in HIV-1 Persistence: Reservoir Support, Viral Sequestration, and Therapeutic Opportunities.Viruses · 2026Review
- Ulva fasciata litter decomposition fuels microbial restructuring and antibiotic resistance proliferation in mariculture sediment.Antonie van Leeuwenhoek · 2026Article
- Limited Sex-Based Differences in Viral Outcomes of ART-Treated SIV/SHIV Infection.The Journal of infectious diseases · 2026Article
- AZD5582 robustly reactivates latently infected cells and clears the majority of those reactivated from the SIV reservoir.bioRxiv : the preprint server for biology · 2026Article
- HIV controllers, lessons learnt from the lymphoid tissues.Current opinion in HIV and AIDS · 2026Review
- Article
- Article
- Astragalus polysaccharide promotes latent HIV-1 reactivation via exosome-mediated modulation of the PI3K/AKT/NF-κB axis.Extracellular vesicles and circulating nucleic acids · 2026Article
- Combining spironolactone to antiretroviral therapy accelerates HIV decay in humanized mice.Emerging microbes & infections · 2025Article
- Identification of inducible HIV reservoirs in tonsillar, intestinal and cervical tissue models of HIV latency.Nature communications · 2025Article
- A TCR-mimic bispecific antibody reduces HIV-1 provirus and delays viral rebound in HLA-matched humanized mice.bioRxiv : the preprint server for biology · 2025Article
- Impact of the IL-15 superagonist N-803 on lymphatic reservoirs of HIV.JCI insight · 2025Article
- Immune-mediated strategies to solving the HIV reservoir problem.Nature reviews. Immunology · 2025Review
- HIV-1 Tat: Molecular Switch in Viral Persistence and Emerging Technologies for Functional Cure.International journal of molecular sciences · 2025Review
- Characterizing resistant cellular states in nasopharyngeal carcinoma during EBV lytic induction.Oncogene · 2025Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
28 authors at 7 institutions in 1 country.
Julia Bergild McBrienEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Maud MavignerDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Lavinia FranchittiEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
S Abigail SmithEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Erick WhiteEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Gregory K TharpEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Hasse WalumEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Kathleen Busman-SahayVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.
Christian R Aguilera-SandovalInternational Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for AIDS Research, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
William O ThayerInternational Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for AIDS Research, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Rae Ann SpagnuoloInternational Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for AIDS Research, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Martina KovarovaInternational Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for AIDS Research, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Angela WahlInternational Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for AIDS Research, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Barbara CervasiEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
David M MargolisInternational Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for AIDS Research, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Thomas H VanderfordEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Diane G CarnathanEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Mirko PaiardiniEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
John H LeeNantKwest, Culver City, CA, USA.
Jeffrey T SafritNantKwest, Culver City, CA, USA.
Steven E BosingerEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Jacob D EstesVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.
Cynthia A DerdeynEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
J Victor GarciaInternational Center for the Advancement of Translational Science, Division of Infectious Diseases, Center for AIDS Research, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Deanna A KulpaEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Ann ChahroudiDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Guido SilvestriEmory Vaccine Center and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA. gsilves@emory.edu.
Emory University · USUniversity of North Carolina at Chapel Hill · USImmunityBio (United States) · USChildren's Center · USFrederick National Laboratory for Cancer Research · USOregon Health & Science University · USOregon National Primate Research Center · US
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MUpgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MB and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection - Administrative SupplementUM1AI124436 · NIAID · EMORY UNIVERSITY · PI AMARA, RAMA RAO, HUNTER, ERIC · 2016 to 2021
$42.3MCollaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2MViral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Joyce Kimberly Cohen · 2018 to 2026
$17.5MAntiviral role of CD8+ T cells in ART-treated SIV-infected macaquesR01AI125064 · NIAID · EMORY UNIVERSITY · PI SILVESTRI, GUIDO · 2016 to 2025
$8.7MThe Role of Human Gut Microbiota in HIV-1 Rectal Acquisition, Replication, and PathogenesisR01AI123010 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WAHL, ANGELA RAQUEL · 2016 to 2020
$3.7MMechanisms of SIV suppression by CD8+ lymphocytesR01AI090797 · NIAID · EMORY UNIVERSITY · PI SILVESTRI, GUIDO · 2010 to 2013
$3.2MRole of Myeloid Cells in HIV latency in the Periphery and the CNSR01MH108179 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARCIA-MARTINEZ, J. VICTOR · 2015 to 2019
$2.7MPlug & Purge: In Vivo Targeting of Active HIV Reservoirs That Persist Despite ARTR01AI111899 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARCIA-MARTINEZ, J. VICTOR · 2014 to 2018
$2.5MCCR NIH HHS HHSN261200800001CNCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261200800001ENIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI090797NIAID NIH HHS R01 AI111899NIAID NIH HHS R01 AI123010NIAID NIH HHS R01 AI125064NIAID NIH HHS R01 AI143414NIAID NIH HHS UM1 AI124436NIAID NIH HHS UM1 AI126619NIH HHS P51 OD011092NIH HHS P51 OD011132NIH HHS S10 OD025002NIH HHS S10 OD026799NIH HHS U42 OD011023NIMH NIH HHS R01 MH108179
Abstract
Human immunodeficiency virus (HIV) persists indefinitely in individuals with HIV who receive antiretroviral therapy (ART) owing to a reservoir of latently infected cells that contain replication-competent virus
Indexed as
Virus ReplicationAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHIV InfectionsHumansInterleukin-15Lymphocyte DepletionMacaca mulattaMiceSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVirus LatencyInterleukin-15
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.